Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.61, while Inovio Pharmaceuticals Inc trades at $0.79 (market cap $78.55M). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| HYG | INO | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $81.32 | $2.87 |
52-Week Low | $78.72 | $0.66 |
Market Cap | — | $78.55M |
Enterprise Value | — | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $79.61, up 0.16% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent dividends include $0.38 paid in August 2026. News highlights bond market volatility amid oil price swings and inflation data, with HYG facing criticism for underperformance versus peers on expenses and yield.
The outlook is cautious due to high-yield bond risks from rising rates and economic uncertainty. Opportunities exist for income seekers, but downside risks are elevated with support at $79. Investors should weigh HYG's liquidity against weaker metrics compared to alternatives.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
